AGC Inc. completed the acquisition of 93.2% in MolMed S.p.A. from Finanziaria d'investimento Fininvest S.p.A. and others for approximately 220 million.
Centerview Partners UK LLP acted as financial advisor and fairness opinion provider to MolMed S.p.A. Cleary Gottlieb represented Centerview Partners as financial advisor to the board of directors of MolMed S.p.A. Nicola Brunetti of Gattai, Minoli, Agostinelli & Partners acted as legal advisor to MolMed S.p.A. Umberto Penco Salvi and Stefano Parrocchetti Piantanida of Clifford Chance Law Office acted as legal advisors to AGC Inc. Luca Fossati, Luca Liistro and Gianfilippo Pezzulo of Chiomenti Studio Legale acted as legal advisors to Finanziaria d'investimento Fininvest S.p.A. Morrow Sodali S.p.A acted as information agent for MolMed. JPMorgan Securities Japan Co., Ltd. acted as financial advisor for AGC Inc.
AGC Inc. (TSE:5201) completed the acquisition of 93.2% in MolMed S.p.A. (BIT:MLM) from Finanziaria d'investimento Fininvest S.p.A. and others for approximately 220 million on July 24, 2020. As per terms, 432.1 million shares have been tendered and the minimum threshold condition is already fulfilled. The consideration will be paid on July 31, 2020. As of July 29, 2020, AGC Inc. has requested the remaining shareholders of MolMed S.p.A. for the compulsory acquisition of remaining stock for 16.25 million. The compulsory acquisition will commence from August 31, 2020 to September 18, 2020. As of September 18, 2020, AGC Inc. has achieved the minimum level of 95% stake. Now, AGC Inc. will go for squeeze out for the remaining stake and will complete the acquisition of 100% stake of MolMed S.p.A. AGC Inc. completed the acquisition of 100% stake in MolMed S.p.A. on September 30, 2020. Upon completion, MolMed's entity name has been changed to AGC Biologics S.p.A.